The use of trastuzumab affected by health insurance policy in Jiangsu Province of China

BACKGROUND: Breast cancer recurrence and mortality have been shown to decrease after trastuzumab treatment in human epidermal growth factor 2 (HER2)-positive early-stage breast cancer (EBC) patients. In Jiangsu Province, trastuzumab has been subsidized for patients with HER2-positive EBC since 2013....

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yiqin, Zheng, Mingjie, Zhan, Xiang, Liu, Ying, Cao, Susheng, Shao, Qing, Meng, Dong, Jin, Liyan, Xu, Lingyun, Yi, Tongbo, Xie, Hui, Wang, Shui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798405/
https://www.ncbi.nlm.nih.gov/pubmed/35116280
http://dx.doi.org/10.21037/tcr-20-3329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798405/
https://www.ncbi.nlm.nih.gov/pubmed/35116280
http://dx.doi.org/10.21037/tcr-20-3329

Ejemplares similares